This website uses cookies. By using the site you are agreeing to our Privacy Policy.

HOME >> Investor Relations >> Top Message >> Message Archive (April 1, 2014)


To Our Investors - April 1, 2014 -

First, I would like to express my sincere appreciation to all the shareholders who took time out of their busy schedule to attend the extraordinary shareholders’ meeting of the Japan Tissue Engineering Co., Ltd. (J-TEC) that was held on March 27. I also would like to thank them for the insightful comments and valuable feedback received during the meeting.

Focusing on numbers in 2014

In FY2013, we enjoyed steady growth in our business. Our autologous cultured epidermis, JACE, recognized as one option for burn therapy, was the major contribution to the success of our business. The autologous cultured cartilage, JACC, finally entered the market after thirteen years of trials and tribulations. There were major changes in the environment surrounding the regenerative medicine industry, including the enactment of the Revised Pharmaceutical Affairs Act in November.

J-TEC will focus on numbers in FY2014 ever more than before to develop our business. Our Board of Directors will manage the company this year emphasizing on profitability. One of our objectives for FY2014 is to put our JACC (launched in April 2013) sales on track and have this product as our primary source of revenue. We are also planning to develop the overseas business that we have been exploring for the last several years, as well as to take full advantages of our collaboration with Fujifilm, our largest shareholder. Furthermore, we are aiming to obtain approval for another product following JACE and JACC and put it to market as soon as possible by utilizing the early approval (conditional/fixed term approval) system that became effective under the Revised Pharmaceutical Affairs Act.

J-TEC would never have been able to survive for the last fifteen years since our establishment without the support of our stakeholders. We are confronted with a choice at every stage during the course of managing a company. We will continue to incorporate the valuable opinions of our stakeholders in our future decisions considering what ways to take to promote our business further.

New team members

New team members

On April 1, 2014, J-TEC welcomed eleven new employees. We hire individual fresh out of college every year and provide them with thorough training. I believe that it is necessary to bring in “new blood” every year in order to develop our business and to maintain the viability of our organization. Our technology and expertise, as well as our corporate culture, are passed down from senior employees to all new incoming staff, and these new employees strengthen horizontal ties to each other beyond the departments they are assigned to.

J-TEC hires a total of approximately twenty-five new employees every year. Those include new graduates hired in April, and each of those individuals strives to be a professional in their field. J-TEC not only creates products consisting of human cells and contributes to the tissue engineering industry but also develops human resources.

April 1, 2014
Yosuke Ozawa
President & CEO
Japan Tissue Engineering Co., Ltd.